Neurana Pharmaceuticals, Inc.

38 articles with Neurana Pharmaceuticals, Inc.

• 

  Neurana, Aurobindo and ORIC Face Tough Decisions, Layoffs

  3/23/2022

  Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.

• Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study

  3/22/2022

  Neurana Pharmaceuticals, today announced that the Phase 3, RESUME-1, clinical study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions, failed to meet its primary and key secondary endpoints.

• Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study

  11/29/2021

  Neurana Pharmaceuticals today announced it has completed enrollment of its 1,000 patient Phase 3 RESUME-1 Study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

• Neurana Pharmaceuticals to Present at Piper Sandler Healthcare Conference

  11/24/2021

   Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the 33rd Annual Piper Sandler Healthcare Conference and participate in one-on-one meetings with investors.

• Neurana Pharmaceuticals to Present at Wells Fargo Virtual Healthcare Conference - Sep 02, 2021

  9/2/2021

  Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, announced that Craig Thompson, President and Chief Executive Officer, will present at the Wells Fargo Virtual Healthcare Conference and participate in one-on-one meetings with investors.

• Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week

  8/30/2021

   Neurana Pharmaceuticals today announced the presentation of scientific abstracts at two congresses, the 28th Annual Napa Pain Conference August 27-28th , 2021, and PAIN Week September 7-11th , 2021. 

• Neurana Pharmaceuticals to Participate at the SVB Leerink Conference

  7/19/2021

  Neurana Pharmaceuticals, Inc. today announced participation at the SVB Leerink Biopharma Private Company Connect. The conference takes place virtually July 21st -22 nd.

• Neurana Pharmaceuticals to Participate at William Blair Biotech Conference

  7/12/2021

  Neurana Pharmaceuticals, Inc. today announced participation at the William Blair Biotech Focus Conference. The conference takes place virtually July 14-15 th .

• Neurana Pharmaceuticals Announces Publication in Pain Management

  7/7/2021

  Neurana Pharmaceuticals today announced the publication of a manuscript, "RESUME-1: A Phase III Study of Tolperisone in Treatment of Painful, Acute Muscle Spasms of the Back" in the journal of "Pain Management".

• Neurana Pharmaceuticals to Present at American Society of Interventional Pain Physicians Meeting

  6/25/2021

  Neurana Pharmaceuticals, today announced the acceptance and presentation of a scientific abstract entitled, "The Effects of Tolperisone on Simulated Driving Performance, Drowsiness, and Cognitive Function: Comparison with Cyclobenzaprine and Placebo in a Phase 1, Randomized, 4-Period, Crossover Study" at the 23rd Annual American Society of Interventional Pain Physicians Meeting

• Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

  6/7/2021

   Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000 subjects have been enrolled in the Phase 3, RESUME-1 clinical study of tolperisone

• Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors

  6/1/2021

  Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of Georgia Erbez and Elizabeth (Liz) Cermak to its Board of Directors. Ms. Erbez and Ms. Cermak are accomplished, experienced life science executives and board directors.

• Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference

  5/11/2021

  Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21st Annual Pain Therapeutics Conference.

• Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study

  12/21/2020

  Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled in the Phase 3, RESUME-1, clinical study of tolperisone, a novel, non-opioid, centrally acting muscle relaxant in clinical development for the treatment of symptoms associated w

• Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

  12/8/2020

  - Tolperisone was comparable to placebo on driving performance; cyclobenzaprine, market leading skeletal muscle relaxant, was significantly worse at all time points - Tolperisone similar to placebo on three measures of sleepiness whereas cyclobenzaprine displayed significantly more sleepiness

• Neurana Pharmaceuticals to Present at Piper Sandler 32nd Annual Healthcare Conference

  11/24/2020

  Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the Piper Sandler 32nd Annual Healthcare Conference and participate in one-on-one meetings with investors

• Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research

  11/23/2020

   Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms of the lower back, in the Journal of Pain Research. "The published clinical data

• Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference

  9/2/2020

   Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the acceptance of two scientific abstracts at the PAINWeek® 2020 National Conference which will take place virtually September 11-13, 2020 . Details of the poster presentations are as follows:

• Neurana Pharmaceuticals to Present at Solebury Trout Private Company Showcase

  8/4/2020

   Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson , President and Chief Executive Officer, will present at the Solebury Trout Private Company Showcase and participate in one-on-one meetings with investors. The conference takes place vi

• Neurana Pharmaceuticals to Present at Upcoming Investor Conference

  7/30/2020

  Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson , President and Chief Executive Officer, will present at the LifeSci Partners Summer Symposium. The conference takes place virtually on August 5 th .  The details of Neurana's presenta